Merck KGaA's Mavenclad stakes its claim in competitive MS market by Kyle Blankenship Thursday, March 5, 2020 Competing with multiple blockbusters in multiple sclerosis, Merck KGaA's Mavenclad is making a name for itself with skyrocketing sales.
Biogen wins Tecfidera patent challenge from Mylan; shares jump by Eric Sagonowsky Wednesday, February 5, 2020 Biogen investors have been on a wild ride in recent months, and on Wednesday they experienced their first major jolt in 2020.
Biogen's Tecfidera holds its own in MS as competition looms by Arlene Weintraub Thursday, January 30, 2020 Despite recent launches of rival MS drugs, Biogen is maintaining its market share, even as it spends big to prep for an expected Alzheimer's debut.
Which new MS drug do doctors like best? You might be surprised by Angus Liu Tuesday, November 19, 2019 A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.
Merck KGaA's MS launch Mavenclad offsets Rebif sales shortfall by Angus Liu Thursday, November 14, 2019 Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.
Biogen wins FDA nod for Tecfidera follow-up as MS threats linger by Eric Sagonowsky Wednesday, October 30, 2019 Biogen's MS business has been treading water and its top-selling Tecfidera might face early generics. But now a follow-up med has nabbed FDA approval.
Biogen's Tecfidera is safe, effective after 10-plus years: study by Eric Sagonowsky Wednesday, September 11, 2019 Tecfidera has managed to keep growing sales as competition in multiple sclerosis intensified. Now, Biogen is touting data its new rivals can't match.
Stung by aducanumab flop, Biogen execs confront their fears by Eric Sagonowsky Wednesday, April 24, 2019 After Biogen's Alzheimer's disease trial failure last month, executives are working to ease investor concern about the company's future.
An already big immunology market is only getting bigger: analyst by Angus Liu Thursday, April 4, 2019 Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
